MAP3K12 and sensory peripheral neuropathy: Given the numerous preclinical studies that identified DLK as a promising therapeutic target6,7,11,12,44, the number of patients who experienced sensory neuropathy and other adverse events in a recent clinical trial of a DLK kinase domain inhibitor was disappointing16.